Close the gap for routine mumps vaccination in Japan

References

• Galazka AM, Robertson SE, Kraigher A. Mumps and mumps vaccine: a global review. Bull World Health Organ. 1999;77:3–14.
   PubMed Web of Science ®Google Scholar
• Japan Pediatric Society. Vaccination Schedule: vaccination Schedule Recommended by the Japan Pediatrics Society [Internet]. Tokyo: Japan Pediatric Society; 2018 [cited 2019 Nov 27]. Available from: https://www.jpeds.or.jp/uploads/files/20180801_JPS%20Schedule%20English.pdf
   Google Scholar
• Fujmaga T, Motegi Y, Tamura H, Kuroume T. A prefecture-wide survey of mumps meningitis associated with measles, mumps and rubella vaccine. Pediatr Infect Dis J. 1991;10:204–09.
   PubMed Web of Science ®Google Scholar
• Sugiura A, Yamada A. Aseptic meningitis as a complication of mumps vaccination. Pediatr Infect Dis J. 1991;10:209–13.
   PubMed Web of Science ®Google Scholar
• Ueda K, Miyazaki C, Hidaka Y, Okada K, Kusuhara K, Kadoya R. Aseptic meningitis caused by measles-mumps-rubella vaccine in Japan. Lancet. 1995 Sep 9;346(8976):701–02.
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Commentary: is Japan deaf to mumps vaccination? Pediatr Infect Dis J. 2009 Mar;28(3):176.
   PubMed Web of Science ®Google Scholar
• Morimoto N. Present status of hearing loss due to mumps virus infection in Japan. Clin Virol. 2017;45:326–30. Japanese.
   Google Scholar
• Fine PE. Herd immunity: history, theory, practice. Epidemiol Rev 1993;15:265–302.
   PubMed Web of Science ®Google Scholar
• Anderson RM, May RM. Immunisation and herd immunity. Lancet. 1990;335:641–45.
   PubMed Web of Science ®Google Scholar
• Rotbart HA. Viral meningitis. Semin Neurol. 2000;20:277–92.
   PubMed Web of Science ®Google Scholar
• Vartiainen E, Karjalainen S. Prevalence and etiology of unilateral sensorineural hearing impairment in a Finnish childhood population. Int J Pediatr Otorhinolaryngol. 1998;43:253–59.
   PubMed Web of Science ®Google Scholar
• Levitt LP, Mahoney DH Jr, Casey HL, Bond JO. Mumps in a general population. A sero-epidemiologic study. Am J Dis Child. 1970;120:134–38.
   PubMedGoogle Scholar
• World Health Organization. Media Center: immunization coverage [Internet]. Geneva: World Health Organization; 2019 [cited 2019 Nov 27]. Available from: https://www.who.int/en/news-room/fact-sheets/detail/immunization-coverage
   Google Scholar
• Peltola H, Jokinen S, Paunio M, Hovi T, Davidkin I. Measles, mumps, and rubella in Finland: 25 years of a nationwide elimination programme. Lancet Infect Dis. 2008;8:796–803.
   PubMed Web of Science ®Google Scholar
• Damm O, Witte J, Wetzka S, Prosser C, Braun S, Welte R, et al. Epidemiology and economic burden of measles, mumps, pertussis, and varicella in Germany: a systematic review. Int J Public Health. 2016Sep, 61(7), 847–60.
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Third Dose of MMR Vaccine for Mumps Control. N Engl J Med. 2017 Dec 14;377(24):2403.
   PubMedGoogle Scholar
• Cardemil CV, Dahl RM, James L, Wannemuehler K, Gary HE, Shah M, et al. Effectiveness of a Third Dose of MMR Vaccine for Mumps Outbreak Control. N Engl J Med. 2017 Sep 7;377(10):947–56.
   PubMed Web of Science ®Google Scholar
• Kadri SM, Rehman SU, Rehana K, Brady AH, Chattu VK. Should Mumps Be Higher Up on the Public Health Agenda in India? A Concern for Global Health Security. Med Sci (Basel). 2018 Aug 7;6:3.
   PubMedGoogle Scholar
• Vaidya SR, Hamde VS. Is it Right Time to Introduce Mumps Vaccine in Indias Universal Immunization Program? Indian Pediatr. 2016 Jun 8;53(6):469–73.
   PubMed Web of Science ®Google Scholar
• Okabayashi H, Komada K, Kidokoro M, Kitamura T, Miyano S, Ito T, et al. Seroprevalence of mumps before the introduction of mumps-containing vaccine in Lao PDR: results from a nationwide cross-sectional population-based survey. BMC Res Notes. 2019 Mar 19;12(1):155.
   PubMedGoogle Scholar
• National Institute of Infectious Diseases. Infectious disease surveillance annual report [Internet]. Tokyo: National Institute of Infectious Disease, Japan; 2019 [cited 2019 Dec 2]. Available from: https://www.niid.go.jp/niid/ja/ydata/8110-report-jb2017.html
   Google Scholar
• Kanzaki J, Nomura Y. Incidence and prognosis of acute profound deafness in Japan. Auris Nasus Larynx. 1986;13:71–77.
   PubMedGoogle Scholar
• Baba K, Okuno Y, Tanaka-Taya K, Okabe N. Immunization coverage and natural infection rates of vaccine-preventable diseases among children by questionnaire survey in 2005 in Japan. Vaccine. 2011;29:3089–92.
   PubMed Web of Science ®Google Scholar
• Morikawa Y, Morino S, Ito K, Furuichi M, Miyokawa S, Shoji T, et al. Trends in varicella and mumps vaccination rates in children under 3 years of age in a tertiary children’s hospital in Japan. Pediatr Int. 2019Sep, 61(9), 882–88.
   PubMed Web of Science ®Google Scholar
• Kitano T, Nishikawa H, Onaka M, Ishihara M, Nishiyama A, Yoshida S. Questionnaire survey on mumps vaccination for parents in Nara prefecture, Japan. Pediatr Int. 2018 Apr;60(4):362–65.
   PubMed Web of Science ®Google Scholar
• Hashimoto S, Kawado M, Murakami Y, et al. Incidence of infectious diseases estimated by the surveillance data in 2002-2004 in Japan. Nihon Koshu Eisei Zasshi. 2006;53:794–99.
   PubMedGoogle Scholar
• Usami SI, Kitoh R, Moteki H, Nishio SY, Kitano T, Kobayashi M, et al. Etiology of single-sided deafness and asymmetrical hearing loss. Acta Otolaryngol. 2017;137(sup565):S2–S7.
   PubMed Web of Science ®Google Scholar
• Morita S, Fujiwara K, Fukuda A, Fukuda S, Nishio SY, Kitoh R, et al. The clinical features and prognosis of mumps-associated hearing loss: a retrospective, multi-institutional investigation in Japan. Acta Otolaryngol. 2017;137(sup565):S44–S47.
   PubMed Web of Science ®Google Scholar
• Rubin SA, Plotkin SA. Mumps vaccine. In: Plotkin SA, Orenstein W, Offit P, editors. Vaccine. 6th ed. Saunders (Philadelphia); 2013. p. 419–446.
   Google Scholar
• Ong G, Goh KT, Ma S, Chew SK. Comparative efficacy of Rubini, Jeryl-Lynn and Urabe mumps vaccine in an Asian population. J Infect. 2005 Nov;51(4):294–98.
   PubMed Web of Science ®Google Scholar
• Dourado I, Cunha S, Teixeira MG, Farrington CP, Melo A, Lucena R, et al. Outbreak of aseptic meningitis associated with mass vaccination with a Urabe-containing measles-mumps-rubella vaccine: implications for immunization programs. Am J Epidemiol. 2000;151(5):524–30.
   PubMed Web of Science ®Google Scholar
• Tesovic G, Begovac J, Bace A. Aseptic meningitis after measles, mumps, and rubella vaccine. Lancet. 1993;341:1541.
   PubMed Web of Science ®Google Scholar
• Black S, Shinefield H, Ray P, Lewis E, Chen R, Glasser J, et al. Risk of hospitalization because of aseptic meningitis after measles–mumps–rubella vaccination in one- to two-year-old children: an analysis of the Vaccine Safety Datalink (VSD) Project. Pediatr Infect Dis J. 1997;16:500–03.
   PubMed Web of Science ®Google Scholar
• Ihara T. Mumps vaccine effectiveness and adverse events: the need for 2-dose vaccination. Nihon Syounikai Kaihou. 2015;49:55–60. Japanese.
   Google Scholar
• Muta H, Nagai T, Ito Y, Ihara T, Nakayama T. Effect of age on the incidence of aseptic meningitis following immunization with monovalent mumps vaccine. Vaccine. 2015;33:6049–53.
   PubMed Web of Science ®Google Scholar
• Nagai T, Okafuji T, Miyazaki C, Ito Y, Kamada M, Kumagai T, et al. A comparative study of the incidence of aseptic meningitis in symptomatic natural mumps patients and monovalent mumps vaccine recipients in Japan. Vaccine. 2007 Mar 30;25(14):2742–47.
   PubMed Web of Science ®Google Scholar
• Ozaki T, Goto Y, Nishimura N, Nakano T, Kumihashi H, Kano M, et al. Effects of a Public Subsidy Program for Mumps Vaccine on Reducing the Disease Burden in Nagoya City, Japan. Jpn J Infect Dis. 2019 Mar 25;72(2):106–11.
   PubMed Web of Science ®Google Scholar
• Toscani L, Batou M, Bouvier P, Schlanepfer A. Comparison of the efficacy of various strains of mumps: a school survey.Soz. Praventivmed. 1996;41:341–47.
   PubMedGoogle Scholar
• Chamot E, Toscani L, Egger P, Germann D, Bourquin C. Estimation of the efficacy of three strains of mumps vaccines during an epidemic mumps in the Geneva canton (Switzerland). Rev Epidemiol Sante Publique. 1998;46:100–07.
   PubMed Web of Science ®Google Scholar
• Schlegel M, Osterwalder JJ, Galeazzi RL, Vernazza PL. Comparative efficacy of three mumps vaccine during disease outbreak in eastern Switzerland: cohort study. BMJ. 1999;319(7206):352.
   Google Scholar
• Harling R, White JM, Ramsay ME, Macsween KF. van den Bosch C. The effectiveness of the mumps component of the MMR vaccine: a case control study. Vaccine. 2005;23:4070–74.
   PubMed Web of Science ®Google Scholar
• Castilla J, Garcia Cenoz M, Arriazu M, Fernandez-Alonso M, Martinez-Artola V, Etxeberria J, et al. Effectiveness of Jeryl Lynn-containing vaccine in Spanish children. Vaccine. 2009;27(15):2089–93.
   PubMed Web of Science ®Google Scholar
• Hviid A, Rubin S, Mühlemann K. Mumps. Lancet. 2008 Mar 15;371(9616):932–44.
   PubMed Web of Science ®Google Scholar
• Cizman M, Mozetic M, Radescek-Rakar R, Pleterski-Rigler D, Susec-Michieli M. Aseptic meningitis after vaccination against measles and mumps. Pediatr Infect Dis J. 1989;8:302–08.
   PubMed Web of Science ®Google Scholar
• Buynak EB, Hilleman MR. Live attenuated mumps virus vaccine. Vaccine Development Proc Soc Exp Biol Med. 1966;123:768–75.
   PubMed Web of Science ®Google Scholar
• Wiedermann G, Ambrosch F. Cost and benefit of measles and mumps immunization in Austria. Bull World Health Organ. 1979;57:625―9.
   PubMed Web of Science ®Google Scholar
• Rivière M, Tretiak R, Levinton C, Fitzsimon C, Leclerc C. Economic benefits of a routine second dose of combined measles, mumps and rubella vaccine in Canada. Can J Infect Dis. 1997 Sep;8(5):257–64.
   PubMedGoogle Scholar
• Kaplan JP, Preblud SR. A benefit-cost analysis of mumps vaccine. Am J Dis Child. 1982;136:362―4.
   Google Scholar
• Zhou F, Reef S, Massoudi M, et al. An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States. J Infect Dis. 2004;189(suppl 1):S131–45.
   PubMedGoogle Scholar
• Sugawara T, Ohkusa Y, Taya K, et al. Cost-effectiveness analysis of routine mumps immunization in Japan. Kansenshogaku Zasshi. 2007;81:555–61.
   PubMedGoogle Scholar
• Hoshi SL, Kondo M, Okubo I. Economic evaluation of vaccination programme of mumps vaccine to the birth cohort in Japan. Vaccine. 2014;32:4189–97.
   PubMed Web of Science ®Google Scholar
• Kitano T, Onaka M, Ishihara M, Nishiyama A, Hashimoto N, Yoshida S. Static model simulation for routine mumps vaccination in Japan: with a result of mumps-related complications in a Japanese community hospital. Clin Exp Vaccine Res. 2017 Jul;6(2):120–27.
   PubMed Web of Science ®Google Scholar
• Kitano T. Dynamic transmission model of routine mumps vaccination in Japan. Epidemiol Infect. 2018 Dec;3:1–8.
   Google Scholar
• Sano T, Sasaki T, Furukawa S, et al. Parents’ intention to take their children to mumps vaccination: influence of information provision and fee. Fukushima Igaku Zasshi. 2012;62(2):46–51. Japanese.
   Google Scholar
• Ministry of Health, Labour and Welfare of Japan. The 32nd Subcommittee Meeting on Adverse Reactions of the Committee on Immunization and Vaccines of the Health Sciences Council. Material 2: about the current status of immunization policy [Internet]. Tokyo: Ministry of Health, Labour and Welfare of Japan; 2019. [cited 2019 Dec 2]. Available from: https://www.mhlw.go.jp/content/10906000/000535717.pdf. Japanese.
   Google Scholar
• Liang Y, Che Y, Yang B, Zhan F, Li H, Guan X, et al. Immunogenicity and Safety of an F-Genotype Attenuated Mumps Vaccine in Healthy 8- to 24-Month-Old Children. J Infect Dis. 2019 Jan 1;219(1):50–58.
   PubMed Web of Science ®Google Scholar
• Sood A, Mitra M, Joshi HA, Nayak US, Siddaiah P, Babu TR, et al. Immunogenicity and safety of a novel MMR vaccine (live, freeze-dried) containing the Edmonston-Zagreb measles strain, the Hoshino mumps strain, and the RA 27/3 rubella strain: results of a randomized, comparative, active controlled phase III clinical trial. Hum Vaccin Immunother. 2017 Jul 3;13(7):1523–30.
   PubMed Web of Science ®Google Scholar
• Saitoh A, Okabe N. Current issues with the immunization program in Japan: can we fill the “vaccine gap”? Vaccine. 2012 Jul 6;30(32):4752–56.
   PubMed Web of Science ®Google Scholar
• Saitoh A, Okabe N. Progress and challenges for the Japanese immunization program: beyond the “vaccine gap”. Vaccine. 2018 Jul 16;36(30):4582–88.
   PubMed Web of Science ®Google Scholar
• Kitano T. Stopping the HPV vaccine crisis in Japan: quantifying the benefits and risks of HPV vaccination in quality-adjusted life-years for appropriate decision-making. J Infect Chemother. 2019 Oct 10;26(3):225–230.
   Web of Science ®Google Scholar